Reducing your Wegovy dose: when it happens, why it helps, and what to expect

What the STEP trial data tells us about dose and tolerability

The STEP 1 trial, published in the New England Journal of Medicine, established the foundational evidence for semaglutide 2.4 mg in weight management. Around 15% average body-weight reduction over 68 weeks was achieved at the maintenance dose, but the trial's structured titration schedule existed precisely because higher doses carry a higher burden of gastrointestinal side effects for many people. The slow escalation from 0.25 mg upward wasn't arbitrary; it was designed to give the gut time to adapt.

What that means in practice is that the licensed prescribing model already builds in an expectation of individual variability. The Wegovy SmPC, held on the Electronic Medicines Compendium, states that if a dose increase is not tolerated, returning to the previous dose is an option, and that the 2.4 mg maintenance level is a target, not a requirement. People who stay on 1.7 mg long-term, for example, because it offers a better balance of benefit and tolerability, are doing so within the clinical framework. Weight loss at 1.7 mg is lower on average than at 2.4 mg, but it remains clinically meaningful for many. The question a prescriber asks isn't "why are you reducing?" but "what's the right dose for this person, at this moment?"

Side effects typically peak in the days after a dose increase, then ease. Knowing that pattern matters. If symptoms are still severe after two to three weeks at a new dose, that's a different signal from discomfort in the first week.

The most common reasons a prescriber might suggest stepping back

Persistent nausea and vomiting head the list. Diarrhoea, significant fatigue, or an inability to eat enough to stay nourished are also reasons a clinician takes seriously. The NHS medicines page for semaglutide notes these gastrointestinal effects as the most commonly reported, and flags that they are generally most pronounced when starting or increasing the dose.

There is a separate, less-discussed reason too: some people find their appetite suppression is adequate at a lower dose and their weight is still moving. In that case, there is no clinical rationale to push to a higher strength that brings more side effects. A prescriber weighing this considers the rate of weight loss, how long the person has been at the current dose, and whether the 5% threshold for continuing treatment (referenced in NICE's guidance) is being met.

A practical point worth naming: life has a rhythm. Someone starting a new dose the week before a holiday, or right before a demanding stretch at work, might reasonably discuss timing with their prescriber rather than pushing through a difficult adjustment period alone. That kind of conversation is what clinical oversight is for. You can read more about the full dose schedule for Wegovy on our Wegovy dose guide.

How a dose reduction works in practice, and what it doesn't mean for your progress

Stepping down doesn't erase the progress made at a higher dose. The medicine is still active; appetite suppression continues, just at a different level of intensity. The prescriber will usually suggest staying at the reduced dose for at least four weeks before reassessing, partly to let side effects settle fully and partly to get a clearer read on how the body is responding.

Re-escalation is possible later if the lower dose is well-tolerated and the person wants to try again. Nothing is locked in. If you want to understand how individual injections are set up and administered, our guide to how the Wegovy pen dose works explains the delivery mechanism in detail. The titration schedule exists in both directions, and returning to a higher dose is a clinical conversation, not an automatic step. Our detailed page on whether reducing your Wegovy dose is the right call covers the decision framework in more depth.

What changes is the monitoring. A prescriber reviewing someone on a reduced dose will pay close attention to weight trend over the following weeks. If loss stalls significantly, that's useful data. If you're earlier in the titration journey, it's also worth reading about what to expect at the Wegovy 0.5 mg dose, since that starting phase shapes how people tolerate later increases. If loss continues at a useful rate with far fewer side effects, that may be the right long-term picture. Neither outcome is failure; both are information.

If you're managing Wegovy through our service and want to discuss your current dose, the right first step is to get in touch with our team, or review the full Wegovy overview to understand how our clinical process works. For anyone weighing up treatment options more broadly, our treatment consultation page is the place to start a conversation with our prescribers, and if you're approaching the later stages of titration, our page on the Wegovy 4 dose pen covers what that stage of the schedule involves.